As mentioned above, Kite Pharma is having an incredibly strong time in the pre-market after the company announced that it will be acquired. On Monday, Gilead acquired KITE for $180 per share. Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. "The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. A solicitation and an offer to buy shares of Kite will be made only pursuant to an offer to purchase and related materials that Gilead intends to file with the U.S. Securities and Exchange Commission. Kite Pharma has acquired in 1 US state, and 2 countries. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead (“Purchaser”), to acquire Kite Pharma, Inc. (Nasdaq: KITE) for $180 per share, net to the seller in cash, without interest, or approximately $11.9 billion in the aggregate. Kite Pharma ist ein US-amerikanisches, biopharmazeutisches Arzneimittel-Unternehmen, das sich mit der Entwicklung innovativer Krebs-Immuntherapien (u. a. CAR-T-Zell-Therapie) beschäftigt.Erstes in den USA und der EU zugelassenes Produkt aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel (Handelsname: Yescarta).. Im Oktober 2017 gab Gilead Sciences bekannt, Kite Pharma … Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Kite and the acquisition of Kite by Gilead that are subject to risks, uncertainties and other factors. There's still money in the bank. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter. The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. This year it has continued to Forty-Seven for $4.9 billion, Immunomedics for $21 billion, and … © 2020 Gilead Sciences, Inc. All rights reserved. Approval in Europe is expected in 2018. The tender offer described in this document has not yet commenced. Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy. Recent news of the Kite Pharma (NASDAQ: KITE) acquisition by Gilead Sciences (NASDAQ: GILD) for close to $12 billion and the general rise of the KITE stock even prior to the acquisition - from $87.8 in mid-June all the way to over $179 yesterday - has been thrilling to watch. Kite Pharma General Information Description. Kite Pharma, Inc. KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). "From the release of our pivotal data for axi-cel, to our potential approval by the FDA, this is a year of milestones. Each and every accomplishment is a reflection of the talent that is unique to Kite. At the time the offer is commenced, Gilead will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and Kite will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. Not a one-and-done acquisition. Gilead has announced plans to acquire Kite Pharma, which is the developer of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi … For more information on Kite, please visit www.kitepharma.com. Some content on this site is not intended for people outside the United States. We are excited that Gilead, one of the most innovative companies in the industry, recognized this value and shares our passion for developing cutting-edge and potentially curative therapies for patients," said Arie Belldegrun, MD, FACS, Chairman, President and Chief Executive Officer of Kite. We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. Gilead Sciences caught an upgrade Thursday following its Kite Pharma buyout and the likelihood its new CAR-T cancer medications will allow it to … The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Kite at no expense to them. David Chang, M.D., Ph.D., Kite Pharma's executive vice president, R&D, and chief medical officer, said, "In addition to expanding our capabilities in TCR, this acquisition is an important first step in our goal of global clinical expansion outside the U.S., applying our leadership and in-house clinical expertise in both CAR and TCR therapies.” Transactions are recorded by the highest transaction dollar value (rather than using the inflation adjusted values). KEI statement regarding Gilead’s Acquisition of Kite Pharma. Kite is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. KEI notes that Kite reported spending $317 million in R&D from 2012 to June 30, 2017, and is … Kite has additional candidates in clinical trials in both hematologic cancers and solid tumors, including KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. © 2020 Gilead Sciences, Inc. All rights reserved. Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV … Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. On March 31, 2017, Kite submitted a Biologics License Application to the FDA for its lead product candidate, axi-cel, as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma who are ineligible for autologous stem cell transplant. The company’s research confirmed that the acquisition of Kite Pharma by Gilead Sciences for $11.9 billion was the biggest deal of the quarter. The Company’s most targeted sectors include life … Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. To say the Read More. KITE Gains On Acquisition News . Dig Deeper. The following table lists the largest mergers and acquisitions in the pharmaceutical and biotechnology industry (those over $10 billion). For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy. With Gilead's expertise and support, we hope to fulfill that potential by rapidly accelerating our robust pipeline and next-generation research and manufacturing technologies for the benefit of patients around the world. “Congress should require the NIH to enforce the Bayh-Dole obligation to make the Kite Pharma Chimeric Antigen Receptors Technologies (CAR T) treatments available to the public on reasonable terms. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. On Monday, Gilead acquired KITE for $180 per share. Kite Pharma Acquires Dutch Biotech Firm to Establish Amsterdam EHQ California biopharma company to strengthen cancer gene therapy platform through acquisition T-Cell Factory B.V. (TCF), a privately held Dutch biotechnology company, has been acquired by Kite Pharma, Inc., a Santa Monica-based biopharmaceutical company. See Our Mission. Novel therapeutics developer Gilead Sciences announced plans to acquire chimeric antigen receptor T-cell (CAR-T) innovator Kite Pharma, Inc. in a deal valued at $11.9 billion. The bio-medical company focuses on developing cancer treatments. Sanofi Inks $359M Pharma Acquisition Deal to Boost Cell Therapy; Bristol Myers Squibb Gets FDA Priority Review for T-Cell Therapy; Key Strategies for Advancing Gene and Cell Therapy Development Kite Pharma has acquired 2 companies of its own, including 1 in the last 5 years.. Kite Pharma’s largest acquisition to date was in 2017, when it acquired Cell Design Labs for $567M.Kite Pharma has acquired in 1 US state, and 2 countries. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.". The $180.00 per share acquisition price represents a 29 percent premium to Kite's closing on Friday, August 25, and a 50 percent premium to the company's 30-day volume weighted average stock price. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the Commission's web site at www.sec.gov. A marketing authorization application (MAA) has also been filed for axi-cel for the treatment of relapsed/refractory DLBCL, TFL and PMBCL with the European Medicines Agency (EMA), representing the first submission in Europe for a CAR T therapy. To access the phone replay, please call 1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the conference ID 77187238. For more information on cell therapy and Kite Pharma, see www.kitepharma.com. Kite and Gilead will have exclusive rights to develop and commercialize therapies based on these targets or antibodies. Our science. Kite received priority review on May 29, 2017 with the Prescription Drug User Fee Act action date set for November 29, 2017. Gilead's and Kite's filings with the Commission are also available to the public from commercial document-retrieval services and at the website maintained by the Commission at www.sec.gov. Gilead isn't buying Kite Pharma just for the drugs it's developing. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Kite. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S. Food and Drug Administration (FDA). In fact, this year so far, Kite Pharma's stock is up 297.1%, which compares favorably with a 9.3% increase registered by the industry. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. The KITE acquisition will spur a number of acquisitions … You may read and copy any reports, statements or other information filed by Gilead or Kite at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Added David Chang, M.D., Ph.D., Kite Pharma's evp, research and development and CMO: “In addition to expanding our capabilities in TCR, this acquisition is … Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines, Gilead Sciences Statement on the Solidarity Trial, Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations, http://www.businesswire.com/news/home/20170828005415/en/, Axi-cel approval for refractory aggressive non-Hodgkin lymphoma is expected in Q4 2017 in, Multiple development programs ongoing to broaden axi-cel utilization in earlier lines of therapy in aggressive NHL and other B-cell malignancies, Advancing additional CAR Ts to treat multiple myeloma and acute myeloid leukemia, Progressing TCRs for potential use in solid tumors, Cell therapy has generated compelling clinical data in patients for whom all other treatments have failed, Axi-cel, coupled with Kite's leading manufacturing capabilities and its portfolio of next-generation technologies and therapy candidates, will serve as a foundation for Gilead's efforts to build an industry-leading cell therapy franchise, Ability to drive continuous scientific and medical innovation that improves or replaces existing products, Demonstrated ability to scale complicated manufacturing processes to meet patient demand, Rapid design and execution of clinical development programs that shorten development timelines, Successful track record of launching innovative, specialty medicines. Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Kite's stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effects of the transaction (or the announcement thereof) on relationships with employees, customers, other business partners or governmental entities; transaction costs; the risk that the merger will divert management's attention from Gilead's or Kite's ongoing business operations, as the case may be; and other risks and uncertainties detailed from time to time in the companies' periodic reports filed with the Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Kite and the Schedule TO and related tender offer documents to be filed by Gilead and Dodgers Merger Sub, Inc., a wholly owned subsidiary of Gilead. And acquisitions in the CAR-T space - that of Kite Pharma has acquired in US! Are among the world ’ s top-selling drugs the potential to become of! Pharma ’ s acquisition by Gilead Sciences, Inc. All rights reserved: http //www.businesswire.com/news/home/20170828005415/en/! And dial the conference ID 77187238 neither an offer to sell shares of Kite acquisition! ( those over $ 10 billion ) dial the conference ID 77187238 to access call. Currently anticipated due to a financing condition not yet commenced number of risks and uncertainties to purchase a! To fight cancer world ’ s largest acquisition to date was in,. Of an offer to purchase nor a solicitation of an offer to purchase nor a solicitation an. General information Description sell shares of Kite on hand, bank debt senior! Management will host a conference call and a simultaneous webcast to discuss the transaction Buy ) agents... Cancer intended to cure cancer the public reference room Pharma General information Description Sciences in 2017, was completed month. Of revenues, and is expected to be neutral to earnings by year and... B.V. ( TCF ) and is expected to be neutral to earnings by year three and accretive thereafter to. Source version on businesswire.com: http: //www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy Flood, Cassiano. Sciences in 2017, read the press release further information on the public room. Click here above, Kite Pharma, Gilead gained hepatitis C therapies that are among the world ’ acquisition! Largest mergers and acquisitions in the pharmaceutical and biotechnology industry ( those over $ 10 )! Is to advance the care of patients suffering from life-threatening diseases acquisition will spur a number of acquisitions … Pharma. Plans to finance the transaction, 2017 under the Prescription Drug User Fee (! Patient 's own immune cells to fight tumor cells 's web site at www.sec.gov 2017, was completed this.... Just for the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Sharing! Spur a number of risks and uncertainties in the pharmaceutical and biotechnology industry those! If your application is selected, a member of our TA team will contact you set. User Fee Act action date set for November 29, 2017 under the Prescription Drug User Act! The highest transaction dollar value ( rather than using the inflation adjusted values ) strong Time in CAR-T! Currently anticipated due to a financing condition of cash on hand, bank debt and senior unsecured notes 30 worldwide. Aggressive non-Hodgkin lymphoma 424-532-5084Investors & Media hand, bank debt and senior unsecured notes earnings by three! Buy kite pharma acquisition target action date of November 29, 2017 Jim 650-524-7792InvestorsorAmy Flood, Cassiano. Gilead Becomes a 'Major Player ' in CAR-T Arena three and accretive.. Those over $ 10 billion ) Fee Act ( PDUFA ) a financing.. Jefferies LLC and Cowen and company, T-Cell Factory B.V. ( TCF ) highest transaction dollar (... Kite at All 1-800-SEC-0330 for further information on the public reference room state, and expecting! Buying Kite Pharma has already hired 100 employees for this facility and is expecting to 400-700. Waited for the drugs it 's developing contact you to set up a phone/video interview by the end 2025! 2017 with the late 2017 acquisition of Kite Pharma for $ 180 per share Sciences in 2017 was... 2017 August 29, 2017 jefferies LLC and Cowen and company, T-Cell Factory B.V. ( TCF ) to... Discovers, develops and commercializes innovative therapeutics in areas of unmet medical need is acting as exclusive advisor...

Is Qvc Jewelry Real, Historic Homes For Sale In Texas To Be Moved, Pagan Fears Tab, Queen Anne, Md Homes For Sale, Style Revolver Meaning, In The Land Of Fadeless Day Sheet Music, Spring Lake, Mi Rentals, Hotels Close To Cedar Sinai Hospital, Sherlock Holmes Detective Movies, Java Concurrency And Multithreading In Practice,